Monitor upcoming data readouts for NMRA-511 (AD agitation, Q4 2026) and NMRA-898 (schizophrenia, H2 2026) as key catalysts. Cash runway into Q3 2027 provides no near-term financing urgency, but any clinical setbacks could pressure the stock given the poor historical performance.
Drugs in focus
NMRA drug pipeline →NMRA-511
◆ Mixed Named in this press release- Impact
- Phase
- Phase 1b/2a
- Time to market
- At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials. The drug is still in early clinical development (Phase 1b/2a).
- Next catalyst
- None dated
What to watchWatch for NMRA-511 MAD expansion cohort data in Q4 2026, positive results could drive a significant rally given the stock's ~$1.04 price and 380% implied analyst upside, but negative data would pressure shares. The company has multiple shots on goal (navacaprant, NMRA-898, NMRA-215), so NMRA-511 is not a single-point-of-failure.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $1.60entry
- T+1 · 3mo ago −5.00%α −4.53% · $1.52
- T+5 · 3mo ago +1.88%α +3.24% · $1.63
- T+20 · 2mo ago −37.54%α −35.55% · $0.9994
- T+60 · 8d ago −69.63%α −66.58% · $0.4859
Price Chart
How similar events traded
Executive Summary
Neumora Therapeutics reported Q2 2026 EPS of -$0.23, exactly in line with consensus, with no revenue. Cash and equivalents of $116.8M are expected to fund operations into Q3 2027. Pipeline milestones remain on track for H2 2026, including data readouts for NMRA-511 and NMRA-898, and an IND submission for NMRA-215. Leadership changes include a new CEO and CMO.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.23 in line with consensus of -$0.23
- Cash and cash equivalents of $116.8M as of June 30, 2026; cash runway into Q3 2027
- Net loss improved to $43.1M from $52.7M in Q2 2025
- R&D expense decreased to $29.3M from $38.7M YoY
- NMRA-215 IND submission planned for Q4 2026 with Phase 1 start by end of 2026
- NMRA-511 MAD expansion cohort data in AD agitation expected Q4 2026
- NMRA-898 Phase 1 data in schizophrenia expected H2 2026
- Joshua Pinto, Ph.D., appointed CEO; Doron Sagman, M.D., appointed CMO
Financial Impact
No material financial impact; net loss improved 18% YoY but remains significant relative to cash position.
Risk Factors
- Clinical trial failures or delays for pipeline candidates
- Dilution risk if additional capital is needed beyond current cash runway
- Leadership transition execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345232 |
Track record
14 reports on NMRA
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
- Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
- Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
- Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
- Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 4/10 No price data
- Aug 14, 202613w ago Press Release Neutral 4/10 Viewing Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
- Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
- Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers